Navidea Shares Gain After Terminating Stock Purchase Agreement - Navidea Biopharmaceutical (OTC:NAVB)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Navidea Biopharmaceuticals Inc (NYSE:NAVB) has terminated the Stock Purchase Agreement executed on August 30, 2020.
The investors agreed to purchase up to $25.0 million in shares of Navidea. The initial closings were to occur within forty-five (45) business days.
The investors agreed to purchase an aggregate of 1 million shares at $5.00 per share.
To date, the Company has received only $25,000 of the $5.0 million that was due at the initial closing.
On Tuesday, the Company notified the Investors that it was terminating the Stock Purchase Agreement.
In a separate release, Navidea achieved full enrollment in its NAV3-35 Phase 2b study to complete the healthy subject (normative) database supporting the Company's Rheumatoid Arthritis imaging commercial product development.
The trial has two arms, with Arm 1 designed to acquire hand and wrist planar images from healthy subjects injected with Tc99m tilmanocept.
Arm 2 is a pilot feasibility study to examine the potential of three-dimensional SPECT/CT imaging of the hands and wrists of healthy subjects and patients with RA injected with Tc99m tilmanocept.
Price Action: NAVB shares are up 8.62% at $1.26 during the premarket session on the last check Thursday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!